June 2026

INMUNOTEK has been present at the annual congress of the European Academy of Allergy and Clinical Immunology, EAACI 2026, participating in both the commercial exhibition and the scientific programme. EAACI 2026 took place in Istanbul, Turkey, from 12 to 15 June, with a large number of participants attending from all five continents.
More info

March 2026

INMUNOTEK held a scientific symposium on Uromune® (MV140) during the 10th Congress of the Latin American Association of Pelvic Floor (ALAPP), where its mechanism of action and the available clinical evidence for the prevention of recurrent urinary tract infections were discussed. The event brought together specialists from several Latin American countries and marked the beginning of the product’s introduction into the Peruvian market.
More info

December 2025

The Centre for the Development of Technology and Innovation (CDTI) has approved funding for the project submitted by INMUNOTEK for the clinical development of new mannan-conjugated polymerized allergoids for allergen-specific immunotherapy.
More info

November 2025

INMUNOTEK in the new ranking compiled by the Financial Times and Statista. This ranking includes the 300 European companies with the highest sustained revenue growth between 2014 and 2024. INMUNOTEK was already included in this ranking in the previous edition (2013–2023).
More info

October 2025

The State Research Agency (AEI) has approved the awarding of funding for the project (Ca10ADVANCE) submitted by INMUNOTEK in collaboration with the Complutense University of Madrid and the Biomedical Research Foundation (La Paz University Hospital, Madrid) for the clinical validation of a new circulating tumor marker with prognostic value.
More info